Two years ago, Shire issued two announcements about its medicine for treating Fabry disease, a rare affliction that causes a buildup of fatty material in the autonomic nervous system, eyes, kidneys and cardiovascular system. On the surface, the announcements – one was about plans to market the drug in the U.S. and the other was about patent litigation – appeared unrelated.
Help employers find you! Check out all the jobs and post your resume.
